INVEST NEW DRUG - INVESTIGATIONAL NEW DRUGS
Publications
- 2014
Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors
Ewald, F., Nörz, D., Grottke, A., Hofmann, B. T., Nashan, B. & Jücker, M., 2014, In: INVEST NEW DRUG. 32, 6, p. 1144-54 11 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells
Grabinski, N. & Ewald, F., 2014, In: INVEST NEW DRUG. 32, 6, p. 1096-1104Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2013
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas
Hartmann, J. T., Horger, M., Kluba, T., Königsrainer, A., de Zwart, P., von Weyhern, C. H., Eckert, F., Budach, W. & Bokemeyer, C., 01.12.2013, In: INVEST NEW DRUG. 31, 6, p. 1592-601 10 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
Hartmann, J. T., Kollmannsberger, C., Cascorbi, I., Mayer, F., Schittenhelm, M. M., Heeger, S. & Bokemeyer, C., 2013, In: INVEST NEW DRUG. 31, 3, p. 661-668 8 p., 3.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2012
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias.
Ziegler, P., Chahoud, T., Wilhelm, T., Pällmann, N., Balabanov, M., Wiehle, V., Ziegler, S., Schröder, M., Meier, C., Kolodzik, A., Rarey, M., Panse, J., Hauber, J., Balabanov, S. & Brümmendorf, T. H., 2012, In: INVEST NEW DRUG. 30, 6, p. 2274-2283 6.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2009
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy).
Schilling, G., Bruweleit, M., Harbeck, N., Thomssen, C., Becker, K., Hoffmann, R., Villena, C., Schütte, M., Hossfeld, D., Bokemeyer, C. & De Wit, M., 2009, In: INVEST NEW DRUG. 27, 2, p. 166-172 2.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.
Schultze, A., Decker, S., Wellbrock, J., Horst, A., Vohwinkel, G., Schuch, G., Bokemeyer, C., Loges, S. & Fiedler, W., 2009, In: INVEST NEW DRUG.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2007
Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller, S., Hartmann, U., Mayer, F., Balabanov, S., Hartmann, J. T., Brümmendorf, T. & Bokemeyer, C., 2007, In: INVEST NEW DRUG. 25, 6, p. 519-524 6.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2006
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
Hartmann, J. T., Oechsle, K., Huober, J., Jakob, A., Azemar, M., Horger, M., Kanz, L. & Bokemeyer, C., 05.2006, In: INVEST NEW DRUG. 24, 3, p. 249-53 5 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2005
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines
Mayer, F., Mueller, S., Malenke, E., Kuczyk, M., Hartmann, J. T. & Bokemeyer, C., 06.2005, In: INVEST NEW DRUG. 23, 3, p. 205-11 7 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
- 2003
An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma
Reichardt, P., Oechsle, K., Pink, D., Bokemeyer, C., Schneller, F., Issels, R., Kanz, L. & Hartmann, J. T., 11.2003, In: INVEST NEW DRUG. 21, 4, p. 481-6 6 p.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review